# Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy

> **NCT03348059** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 103 (actual)

## Conditions studied

- Chronic Hepatitis c

## Interventions

- **DRUG:** Direct-acting antiviral therapy

## Key facts

- **NCT ID:** NCT03348059
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-01
- **Primary completion:** 2016-11-30
- **Final completion:** 2017-03-31
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2017-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03348059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03348059, "Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03348059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*